Murphy SA - Search Results

1

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.

Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLE-TIMI 44 Investigators. Wiviott SD, et al. Among authors: murphy sa. Circulation. 2007 Dec 18;116(25):2923-32. doi: 10.1161/CIRCULATIONAHA.107.740324. Epub 2007 Dec 3. Circulation. 2007. PMID: 18056526 Clinical Trial.

2

Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. The TIMI Study Group.

Gibson CM, Ryan KA, Kelley M, Rizzo MJ, Mesley R, Murphy S, Swanson J, Marble SJ, Dodge JT, Giugliano RP, Cannon CP, Antman EM. Gibson CM, et al. Am Heart J. 1999 Jun;137(6):1179-84. doi: 10.1016/s0002-8703(99)70380-7. Am Heart J. 1999. PMID: 10347349

3

Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction.

Gibson CM, Murphy S, Menown IB, Sequeira RF, Greene R, Van de Werf F, Schweiger MJ, Ghali M, Frey MJ, Ryan KA, Marble SJ, Giugliano RP, Antman EM, Cannon CP, Braunwald E. Gibson CM, et al. J Am Coll Cardiol. 1999 Nov 1;34(5):1403-12. doi: 10.1016/s0735-1097(99)00397-6. J Am Coll Cardiol. 1999. PMID: 10551685

4

Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials).

Llevadot J, Giugliano RP, McCabe CH, Cannon CP, Antman EM, Murphy S, Gibson CM. Llevadot J, et al. Am J Cardiol. 2000 Jun 15;85(12):1409-13. doi: 10.1016/s0002-9149(00)00786-4. Am J Cardiol. 2000. PMID: 10856384

5

Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Thrombolysis In Myocardial Infarction.

Gibson CM, Anshelevich M, Murphy S, Luu L, Hynes C, Kliris J, Kermgard S, Otten MH, Antman EM, Cannon CP, Braunwald E; Thrombolysis in Myocardial Infarction. Gibson CM, et al. Am J Cardiol. 2000 Dec 15;86(12):1378-9, A5. doi: 10.1016/s0002-9149(00)01248-0. Am J Cardiol. 2000. PMID: 11113418 Clinical Trial.

6

Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy.

Srinivas VS, Cannon CP, Gibson CM, Antman EM, Greenberg MA, Tanasijevic MJ, Murphy S, de Lemos JA, Sokol S, Braunwald E, Mueller HS. Srinivas VS, et al. Am Heart J. 2001 Jul;142(1):29-36. doi: 10.1067/mhj.2001.116068. Am Heart J. 2001. PMID: 11431653 Clinical Trial.

7

Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes.

Cohen M, Antman EM, Murphy SA, Radley D. Cohen M, et al. Among authors: murphy sa. Am Heart J. 2002 Jan;143(1):63-9. doi: 10.1067/mhj.2002.119767. Am Heart J. 2002. PMID: 11773913 Clinical Trial.

8

Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.

Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Sabatine MS, et al. Among authors: murphy sa. Circulation. 2002 Apr 16;105(15):1760-3. doi: 10.1161/01.cir.0000015464.18023.0a. Circulation. 2002. PMID: 11956114

9

Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction.

Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E; TIMI Study Group. Gibson CM, et al. Among authors: murphy sa. Circulation. 2002 Apr 23;105(16):1909-13. doi: 10.1161/01.cir.0000014683.52177.b5. Circulation. 2002. PMID: 11997276 Clinical Trial.

10

Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.

Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM; TIMI 11A Investigators. Becker RC, et al. Among authors: murphy sa. Am Heart J. 2002 May;143(5):753-9. doi: 10.1067/mhj.2002.120774. Am Heart J. 2002. PMID: 12040334

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

662 results

Search Page